[vc_row][vc_column][vc_column_text]“It’s a momentous achievement for a wearable device that can provide critical data for doctors and peace of mind for you” – those are Apple’s words.

  • So just how useful is it? Well, it seems Janssen Pharmaceuticals (a Johnson & Johnson member company) thinks Apple could be on to something. The company is collaborating with Apple on a research study to investigate whether a new heart health program using an app from Johnson & Johnson in combination with the Apple Watch’s irregular rhythm notifications and ECG app can accelerate the diagnosis and improve health outcomes for approx. 33 million worldwide living with atrial fibrillation (AFib).
  • What’s AFib? Atrial fibrillation is a type of abnormal rhythm of the heart that can lead to stroke and other potentially devastating complications. AFib impacts more than 400,000 Australians.

The multi-year research program will be launched later in 2019. This large-scale program will occur in the U.S. only, and will be designed as a pragmatic randomised controlled research study for individuals aged 65 years or older.

KEY INSIGHT: The study will measure the outcomes of a heart health engagement program with irregular rhythm notifications on Apple Watch; and Assessing the impact of a medication adherence program using an app from Johnson & Johnson.[/vc_column_text][/vc_column][/vc_row]

Related Stories

Featured, Future of MedTech